Drug

Perphenazine

In clinical development

ClassDopamine D2 receptor antagonistEmerging researchLate-stage development

Also known as 2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine, Chlorpiprazine, Etaperazin, Etaperazine+9 more

2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine, Chlorpiprazine, Etaperazin, Etaperazine, Ethaperazine, Perfenazina, Perphenazine-Amitriptyline, Triavil, Trilafon, Perfenazine, Perphenazin, Perphénazine, Perphenazinum.

RxNorm8076 ChEMBLCHEMBL567 ATCN05AB03UNIIFTA7XXY4EZ

Research papers

D(2) dopamine receptor

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

Clinical trial2026-05-28Results posted · ClinicalTrials.gov

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

Clinical trial2025-04-29Results posted · ClinicalTrials.gov

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Ischaemic STROKE (REPO-STROKE IIa)

Clinical trial2024-02-29Primary completion · ClinicalTrials.gov

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Clinical trial2021-03-01Results posted · ClinicalTrials.gov

Pharmacovigilance in Gerontopsychiatric Patients

Clinical trial2017-06-28Terminated · ClinicalTrials.gov

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial

Clinical trial2016-06-22Completed · ClinicalTrials.gov

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Clinical trial2015-04-24Results posted · ClinicalTrials.gov

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

Clinical trial2013-05-01Primary completion · ClinicalTrials.gov

Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study

Clinical trial2013-02-08Results posted · ClinicalTrials.gov

A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Clinical trial2012-09-01Withdrawn · ClinicalTrials.gov

A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

Clinical trial2009-07-21Completed · ClinicalTrials.gov

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Research2005-09-19The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Perphenazine

Aliases & brands

2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazineChlorpiprazineEtaperazinEtaperazineEthaperazinePerfenazinaPerphenazine-AmitriptylineTriavilTrilafonPerfenazinePerphenazinPerphénazinePerphenazinum

RxNorm CUI

8076

ChEMBL ID

CHEMBL567

ATC codes

N05AB03

UNII

FTA7XXY4EZ

Primary mechanism

Dopamine D2 receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

D(2) dopamine receptor

DRD2 · P14416

ANTAGONISTDopamine D2 receptor antagonist

Clinical trials

13 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2025

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 13

Phase 11Phase 22Phase 34Phase 46

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

CompletedPH IVTechnical University of Munichn=212016

Lurasidone Effects on Tissue Glutamate in Schizophrenia

CompletedPH IVUniversity of Texas Southwestern Medical Centern=352016

CompletedPH IVJanssen Scientific Affairs, LLCn=4502013

WithdrawnPH IVOrtho-McNeil Janssen Scientific Affairs, LLC2012

Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study

CompletedPH IVNational Institute of Mental Health (NIMH)n=212009

Recent completions

Trials that read out recently, adding to the completed evidence base.

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

CompletedPH IIIKey trialJennifer Holder-Murrayn=3,3952025

CompletedPH IIIJanssen Scientific Affairs, LLCn=3372019

CompletedPH IVTechnical University of Munichn=212016

Lurasidone Effects on Tissue Glutamate in Schizophrenia

CompletedPH IVUniversity of Texas Southwestern Medical Centern=352016

CompletedPH IVJanssen Scientific Affairs, LLCn=4502013

Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study

CompletedPH IVNational Institute of Mental Health (NIMH)n=212009

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

The New England journal of medicine · 2005 · 3,569 cites

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Olanzapine

Acts on the same molecular target as Perphenazine, with 3 overlapping disease areas.

Shared target3 shared diseases1 shared paper

Quetiapine Fumarate

Acts on the same molecular target as Perphenazine, with 3 overlapping disease areas.

Shared target3 shared diseases1 shared paper

Risperidone

Acts on the same molecular target as Perphenazine, with 3 overlapping disease areas.

Shared target3 shared diseases1 shared paper

Ziprasidone

Studied across 3 of the same disease areas as Perphenazine in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials